Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
B Billemont, J Medioni, L Taillade, D Helley, J B Meric, O Rixe, S Oudard, B Billemont, J Medioni, L Taillade, D Helley, J B Meric, O Rixe, S Oudard
Abstract
Sunitinib, a multitargeted tyrosine-kinase inhibitor, extends survival of patients with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumours. Between October 2005 and March 2007, we retrospectively reviewed blood glucose level variations associated with sunitinib therapy in patients treated for mRCC. Nineteen of the patients had type II diabetes. All 19 patients had a decrease in blood glucose level (mean 1.77 mmol l(-1)) after 4 weeks of treatment. This was followed by re-elevation in the 2-week rest period. After two cycles of sunitinib administration, two patients had stopped blood glucose-lowering drugs whereas five other patients had normalised their blood glucose level. On the basis of pre-clinical data, we hypothesise that several mechanisms could be involved in this process, such as capillary regression of pancreatic islets, IGF-1 modulation through HIF1-alpha or NF-kappaB activation. In addition, a decrease of glucose uptake in the context of concomitant gastrointestinal toxicity cannot be excluded. Glycaemic control should be carefully evaluated in diabetic patients treated with sunitinib, and routine monitoring is warranted.
Figures
References
- Carroll VA, Ashcroft M (2006) Role of hypoxia-inducible factor (HIF)-1alpha vs HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von hippel-lindau function: implications for targeting the HIF pathway. Cancer Res 12: 6264–6270
- Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 9: 734–745
- Gillessen S, Graf L, Korte W, Cerny T (2007) Macrocytosis and cobalamin deficiency in patients treated with sunitinib. N Engl J Med 356(22): 2330–2331
- Hagerkvist R, Sandler S, Mokhtari D, Welsh N (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 21: 618–628
- Hamberg P, de Jong FA, Boonstra JG, van Doorn J, Verweij J, Sleijfer S (2006) Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol 24(18): e30–e31
- Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM (2006) VEGF-dependant plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290: H560–H576
- Leroith D, Accili D (2008) Mechanisms of disease: using genetically altered mice to study concepts of type II diabetes. Nat Clin Pract Endocrinol Metab 3: 164–172
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib vs interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2: 115–124
- Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 21: 2516–2524
- Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 1: 81–83
- Templeton A, Brändle M, Cerny T, Gillessen S (2008) Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 4: 824–825
- Veneri D, Franchini M, Bonora E (2005) Imatinib and regression of type 2 diabetes. N Engl J Med 10: 1049–1050
Source: PubMed